NCT03255551View on ClinicalTrials.gov

Blood Pressure Lowering Effects of Amosartan Regarding Proviso iN Patients With High Blood Pressure

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

December 31, 2015

Conditions
Hypertension
Interventions
DRUG

Amosartan

amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent

All Listed Sponsors
lead

Seoul National University Bundang Hospital

OTHER

NCT03255551 - Blood Pressure Lowering Effects of Amosartan Regarding Proviso iN Patients With High Blood Pressure | Biotech Hunter | Biotech Hunter